Seneca Partners invests £1.2m into biotech start-up SolasCure

Seneca Partners invests £1.2m into biotech start-up SolasCure

£733k invested via Seneca EIS Portfolio Service and £500K via Seneca Growth Capital VCT

Seneca Partners (Seneca), the specialist SME investment business based in the North West, has invested £1.2m into biotech company, SolasCure to support the development of their wound cleaning product, Aurase® through the Seneca EIS Portfolio Service and Seneca Growth Capital VCT.

Seneca’s investment comes as SolasCure is developing proprietary technology leveraging biomimicry and evidence-based medicine to empower health care professionals to treat patients with chronic wounds. Their first investigational product, Aurase®, is a hydrogel containing an enzyme cloned from medical maggots that can be used to support healthcare professionals treating patients with chronic wounds.

Matt Currie, Investment Director at Seneca Partners commented: “SolasCure has the key characteristics of an innovative, young business that the Seneca seeks to invest in. This is a world-class team, producing ground-breaking work in the wound care sector. They have developed a high-quality solution that can be transported, stored and administered in an efficient and effective way, something severely lacking in the treatments available at present. We believe SolasCure’s Aurase® product has the potential to become the go-to solution in this space.”

Dr. Sam Bakri, Executive Chairman and CEO of SolasCure said: “We are delighted to have completed our Series A round, which will help us to move onto the clinical trial stages of product development. We are excited to be working with such knowledgeable and specialist investors, as they join us on our mission to support healthcare professionals with wound care products that significantly improve the health and wellbeing of patients with chronic wounds.”


Risk Warning

The value of an investment may go down as well as up, in which case an investor may not get back the amount invested. Past performance is not a guide to future performance. Investors should seek advice from a qualified financial adviser. Nothing on this website should be construed as investment or tax advice.

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.